Direct answer
Whey, plant and yeast-biomass ingredients can supply dietary protein, but their evidence and practical limitations differ. No eligible independent three-way trial was identified in this targeted review that establishes a universal winner for muscle, strength, weight loss or safety. The cited whey literature is more developed than the cited modern yeast-biomass literature; commercial support is common, and the three yeast reports discussed here are commercially supported. Choose using actual protein content, dietary needs, allergens, tolerability, verified quality and cost. A lack of independent confirmation does not establish ineffectiveness.
Confidence is high in the ingredient and allergy distinctions, moderate in the interpretation of the cited protocols, and low in universal efficacy rankings after strict funding screening. Small trials, different populations and unresolved financial terms limit comparative certainty.
Introduction
The useful question is not simply which name wins. It is: which specific product supplies an appropriate amount of protein, fits the person's diet, and has evidence relevant to the intended outcome?
The three categories are not equally uniform. Whey is a family of milk proteins. “Plant protein” covers many different crops. “Yeast protein” may describe whole inactivated yeast, a concentrated biomass ingredient, an isolate or an extract with a very different composition. Equal scoop sizes may therefore contain different amounts of actual protein.
This comparison excludes manufacturer-, seller- and industry-supported outcome evidence from its independent efficacy verdict, including donated study ingredients. Commercial trials are described for context and to show where claims come from. Government or university affiliation alone does not pass this screen, and a review's independence does not establish that of the trials it pools.
Table of contents
- At-a-glance comparison
- Evidence and funding summary
- Types and forms
- Protein quality and mechanisms
- Benefits by claim
- What works and what does not follow
- Risks interactions and who needs advice
- Doses studied and fair comparisons
- Animal evidence and surrogate outcomes
- Money countries and backers
- Source-credibility scorecard
- Regulatory context
- FAQ
- Sources and limitations
At-a-glance comparison
| Question | Whey | Plant | Yeast biomass protein |
|---|---|---|---|
| Origin | Milk | Legumes, grains, seeds and other crops | Yeast, a fungus |
| Main forms | Concentrate, isolate, hydrolysate; native processing; clear drink format | Soy, pea, rice, seed proteins and blends; isolates/concentrates | Whole inactivated biomass, concentrates/isolates; distinct extracts and hydrolysates |
| Dairy-free by ingredient identity? | No | Usually, but check the complete product and cross-contact | Usually for biomass protein; precision-fermented milk proteins are a separate case |
| Vegan suitability | Dairy whey is not vegan | Depends on the complete formulation | Yeast-biomass ingredients can be non-animal; verify formulation |
| Comparative muscle evidence | The cited whey research spans more settings than the cited modern yeast reports; many studies are sponsored | Ingredient-specific; the purchased-supplement pea pilot is small, and soy-trial supply terms remain unknown | The three reports discussed below have documented commercial support |
| Principal distinctive checks | Milk allergy; lactose amount | Soy/pea/other allergens; actual blend and composition | Ingredient identity; residual RNA/purine specification; yeast allergy |
| Is there a proven universal safest category? | No | No | No |
The table describes categories, not a ranking of brands or a claim that every member has been tested.
Evidence and funding summary
| Evidence question | What the audit found | Funding screen and implication |
|---|---|---|
| A direct independent three-way comparison | None identified in this targeted search | No head-to-head evidence permits a universal whey–plant–yeast league table |
| Whey versus pea | Banaszek: 15 HIFT-trained adults, eight weeks; squat/deadlift improved over time, with no detected source difference | Supplements purchased; no external funding; later gym ownership is an indirect tie. No detected muscle-thickness or body-composition improvement; no unsupplemented control C1 |
| Whey versus soy | Lynch: 61 young untrained adults randomized, 48 completed; 12 weeks of training with leucine-matched whey/soy | SCAN/ASU grants and no declared conflicts; exact grant chain and product procurement remain incompletely traced. No significant source difference, no unsupplemented control, and no equivalence design C2 |
| Wider animal-versus-plant evidence | Reid-McCann 2025: 43 eligible animal-versus-plant trials, with source- and outcome-dependent findings; searches ended in June 2023 | Northern Ireland Department for the Economy PhD support; no conflicts declared. Included-trial finances were not completely cleared here; this is not an independent-only pool C3 |
| Whey versus yeast | Briskey 2024: 116 men aged 40 or older enrolled, 79 completed an eight-week yeast/whey/placebo study. The reported yeast-versus-placebo lean-mass signal was in the lower-background-protein subgroup | Angel Yeast funded; manufacturer-affiliated authors. Whole-cohort within-group changes do not establish superiority over placebo or equivalence to whey C4 |
| Yeast in older adults | Bai 2026: 92 independently ambulatory older adults with low muscle mass, 24 weeks. Walking-speed and SPPB changes differed across groups; muscle mass and handgrip changes did not | Angel Nutritional Fund AF2021001; excluded from independent efficacy verdict. Participants were unblinded, controls maintained usual diet, and these findings do not establish reversal of sarcopenia C5 |
| Acute yeast protein quality | Barsky 2026 preprint v1: yeast met a 20% noninferiority margin for acute phenylalanine oxidation after one participant’s three trials were excluded (n=12). Including all 13 made noninferiority inconclusive | Lesaffre funded and supplied yeast; employee coauthor. Acute whole-body proxy, not direct muscle-biopsy MPS or long-term muscle gain C6 |
| Clear whey superiority | No independent superiority established in this audit | Ingredient sellers describe formulation properties; that evidence does not establish greater muscle gain C7 |
There is deliberately no pooled “muscle gained” bar chart here. Combining different populations, exercise programmes, comparators and follow-up durations would create a misleading impression of a controlled three-way experiment.
Types and forms
Whey: concentrate isolate hydrolysate native and clear
Concentrate and isolate describe purification characteristics. Hydrolysate describes protein broken into smaller peptides; it can begin with different whey ingredients. Native whey describes direct separation from milk. Clear whey is a clear or juice-style formulation, often based on isolate or hydrolysate. These descriptions overlap.
Arla's ingredient pages market isolates for both clear and milky applications and a hydrolysate for clear sparkling drinks. These seller materials establish formulation possibilities only. They do not establish clinical superiority or dairy-free status. C7, C8
Plant: specify the ingredient
Soy, pea, rice, hemp, pumpkin and blended powders should not be treated as a single intervention. A blend can change amino-acid balance, but its name does not specify the ratio, digestibility or amount of protein in the final serving. A whole-food plant-based diet is also different from a powder added to an omnivorous diet.
Yeast: biomass is not every fermented protein
A concentrated yeast-biomass protein is distinct from nutritional yeast flakes, a salty yeast extract, a milligram-dose fermentate and a live probiotic such as Saccharomyces boulardii. Mycoprotein made from filamentous fungi is another category.
Precision fermentation can use a microorganism to make a particular protein. Health Canada's assessment of yeast-produced beta-lactoglobulin illustrates why the finished protein's identity matters: it remains a milk-allergen concern. A fermentation process is not evidence that the output belongs in the yeast-biomass category or is safe for milk allergy. C9
Protein quality and mechanisms
All three can contribute amino acids, but the quantities and relative amino-acid profiles depend on the ingredient. “Contains all essential amino acids,” “high leucine” and “high DIAAS” answer different questions.
Protein-quality scores assess amino-acid adequacy and digestibility against defined reference patterns. They do not measure strength, sustained muscle growth or clinical superiority. FAO’s DIAAS framework prefers true ileal amino-acid digestibility measured in humans; when human measurement is not possible, it specifies growing pigs and then growing rats. The measurement species and reference pattern therefore matter when interpreting a score. C10.
Useful comparisons keep the denominator constant: grams of actual protein rather than grams of flavoured powder, and amino acids per the same quantity. Matching protein, matching leucine and matching calories are different experimental choices. None by itself matches the entire diet, all amino acids or the training programme.
Benefits by claim
Protein adequacy
A suitable product can help fill a dietary protein shortfall. Whether there is a shortfall must be assessed from the whole diet and individual needs. The nutritional role of protein does not make a powder necessary. EU-authorized muscle-growth/maintenance claims apply to qualifying protein foods, not a special benefit exclusive to whey, plants or yeast. C11
Muscle growth and strength
The evidence does not support saying either “all proteins are identical” or “only whey works.” Independent evidence is thinner than the overall literature suggests once sponsor funding and product donations are screened.
The pea pilot and grant-supported soy trial found no significant source differences in their specific training settings, but neither established equivalence or separated supplementation from training alone. The broader review found some source- and outcome-dependent differences; its included trials were not all financially cleared. None of the three yeast reports cited here passes the commercial-support screen. This limits independent comparative confirmation, without establishing that yeast protein has no nutritional value. C1, C2, C3, C4, C5, C6.
Weight loss glucose and recovery
No independently established three-way winner was identified. A powder supplies energy; its practical effect depends on what it replaces and the overall diet. Short-lived changes in fullness, blood glucose, circulating amino acids or muscle protein synthesis cannot substitute for sustained weight change, better diabetes outcomes or improved functional recovery.
Ageing and sarcopenia
Sarcopenia requires clinical assessment of strength, function and muscle measures. Young-volunteer findings cannot simply be applied to frail older adults. Bai’s commercially supported study enrolled independently ambulatory older people with low muscle mass: it found functional differences but no significant between-group muscle-mass or handgrip change. Its usual-diet control and participant unblinding limit interpretation. The plant-versus-animal review did not identify trials measuring sarcopenia itself as an outcome. C3, C5.
Gastrointestinal tolerance
There is no dependable universal tolerability ranking from the evidence audited here. Lactose, fibre, residual cell-wall material, sweeteners and the rest of a product's formulation can matter. A “lighter” clear drink may be a sensory preference without proving less digestive disturbance. Laboratory fermentation or gas measurements do not establish symptoms in people.
What works and what does not follow
| Decision or claim | Defensible reading |
|---|---|
| Choose a product that fits an identified protein need and dietary preference | Reasonable; compare the full formulation and actual protein content |
| Choose a non-dairy option because whey is incompatible with milk allergy | Appropriate in principle, but check the alternative's own allergens and cross-contact |
| Choose clear whey because a juice-style drink is more pleasant | A preference-based choice; no premium clinical effect is established |
| Choose yeast because one marketed quality score is high | Insufficient basis for a clinical ranking |
| Assume every pea–rice blend is equivalent to whey | Requires evidence for the actual blend and outcome |
| Infer the same effect because a small study found P greater than 0.05 | Incorrect; nonsignificance does not prove equivalence |
| Infer safety from organic, natural, vegan or fermented branding | Incorrect; these do not substitute for allergen, composition or batch data |
Risks interactions and who needs advice
Allergy comes before optimization
Ordinary whey remains milk protein in concentrate, isolate, hydrolysed and clear forms. Lower lactose does not remove a milk-protein allergy. Plant alternatives may contain soy or other allergens, and pea can trigger reactions in some people with peanut allergy. No category should be advertised as incapable of allergy. C12, C13
Lactose intolerance differs from milk allergy
Lactose intolerance concerns difficulty digesting milk sugar and differs from an immune reaction to milk protein. Check the finished product’s lactose content and label rather than inferring tolerability from the word isolate or hydrolysed. Arla markets its named HYDRO.Clear hydrolysate as lactose-free; that specific product statement does not establish that hydrolysis itself removes lactose or that every whey hydrolysate is lactose-free. C8, C14.
Yeast-specific RNA and purine checks
Residual nucleic acids depend on processing. US rules for one specified processed baker’s-yeast protein require nucleic acids below 2% of dry weight, alongside other specifications. This is not a universal dose limit or proof that every retail ingredient complies. Whole dried yeast and a low-RNA isolate cannot be assigned the same purine content. People with gout, hyperuricemia or uric-acid stones should discuss the actual product specification and clinical diet; Bai’s trial excluded gout and hyperuricemia, so it does not resolve safety in those groups. C15, C5.
Medicines and clinical diets
For levothyroxine, follow the exact medicine’s instructions and review the complete powder with the prescriber or pharmacist. The cited label names soybean flour and dietary fibre as food components that may reduce absorption, and separately addresses interacting minerals such as calcium and iron. It does not quantify an interaction for every soy isolate or protein powder, nor provide one universal timing rule for all formulations. C16.
For monoamine oxidase inhibitors, concentrated yeast extracts are a specific concern. The tranylcypromine label distinguishes those extracts from ordinary baker's/brewer's yeast; an unfamiliar concentrated product still needs a pharmacist's assessment. C17
Kidney disease, prescribed protein restrictions, significant illness, pregnancy, breastfeeding and children's nutrition require individualized assessment. Products may also add potassium, phosphorus, sodium, vitamins or herbs. Do not change prescribed medicines or disease management based on this comparison.
Contaminants
No class label determines a batch's safety. A meaningful test report specifies the product, lot, laboratory, date, analytes, methods, limits and actual results. A contaminant survey is not a test of every brand and batch, and a certification mark is not a muscle-growth claim. This comparison does not certify any product or repeat category-wide contamination percentages as personal risk estimates.
Doses studied and fair comparisons
There is no independently validated conversion chart saying a fixed gram amount of whey, plant and yeast protein will produce the same result in every person.
Some often-misread research quantities are:
- Banaszek’s pilot provided 24.4 g whey or 24.5 g pea protein twice daily, approximately 49 g supplemental protein per day, alongside habitual food intake. C1.
- Lynch compared 26 g soy protein with 19 g whey protein daily, approximately leucine-matched; those are not equal protein doses C2
- Briskey’s trial provided 40 g supplement powder per day as two 20 g servings; that is neither 40 g twice daily nor automatically 40 g actual protein. C4.
- Bai's commercial older-adult trial used 20 g powder per day, supplying about 15–16 g protein C5
These quantities describe research, not recommended intake. A study testing one dose does not establish a minimum effective amount. A short-term MPS experiment does not establish an absorption ceiling. Food protein, body size, total energy, exercise, age and health all affect how a protocol should be interpreted.
For shopping comparisons, calculate price per the same amount of actual protein, then consider formulation, tolerance and testing. No current price ranking is claimed here because no equivalent products and batches were priced for this review.
Animal evidence and surrogate outcomes
Animal growth, cell signalling and simulated digestion do not establish human clinical efficacy. Composition and digestibility methods can describe an ingredient when their limits are explicit. Acute muscle-biopsy MPS, whole-body indicator amino-acid oxidation (IAAO), and long-term hypertrophy are different endpoints. Barsky’s commercially supported 2026 preprint used an a priori 20% noninferiority margin on acute phenylalanine oxidation: yeast met it in the n=12 analysis after one participant’s three trials were removed, while the all-13-participant analysis was inconclusive. This cannot establish equal muscle growth, and IAAO is not direct muscle-biopsy MPS. C6, C10.
Money countries and backers
Research funding at a glance
23 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Each category has sellers with a commercial stake. Dairy firms, crop-protein suppliers and yeast companies all benefit from favourable results. A funded null result can also be commercially useful. The same funding rule applies regardless of which ingredient wins.
The figure maps selected documented study relationships rather than implying that an entire category has a single owner. Company materials may establish corporate identity or ingredient processing; they do not supply independent efficacy evidence.
Pinckaers’s acute experiment compared pea with milk-protein concentrate, rather than whey. Its TiFN funding included Tereos, Cargill, Kellogg and the Top-sector Agri&Food; industrial partners contributed to study design and product selection, and named authors disclosed additional dairy/PepsiCo ties. Angel’s own 2026 nutrition-fund guide documents company administration and free study samples for that programme. It does not establish the exact historical terms of Bai’s AF2021001 grant. These disclosures identify relevant relationships without demonstrating misconduct. C18, C19, C5.
Arla Foods Ingredients identifies itself as a wholly owned subsidiary of Arla Foods with headquarters in Denmark. Lesaffre’s own family-ownership announcement and its subsidiary’s current history describe a French family-owned group. These are commercial self-disclosures used for corporate identity, not independent clinical evidence. Individual family share percentages and every retail brand’s ownership were not reconstructed. Ingredient origin, manufacturing country and study location must be kept distinct. C20, C21: Lesaffre disclosure, C21: current subsidiary disclosure.
Source-credibility scorecard
Tier and grade describe independence and incentives, not whether an individual measurement is true. Tier 1 is independently funded/no identified relevant stake; Tier 2 indirect ties; Tier 3 an interested party; Tier 4 maker/seller support. Unresolved information remains unknown.
| Sources | Funding or revenue; country | Tier / grade | Proper use and remaining limitation |
|---|---|---|---|
| C1 Banaszek | No external funding; supplements purchased; US | 2 / B | 15-person training pilot; indirect later gym ownership. No unsupplemented control; internal budget not fully traced |
| C2 Lynch | SCAN/ASU grants; US | 2 provisional / B | 61 randomized/48 completed young adults; source comparison, not equivalence. Grant chain and commercial-product supply terms remain unknown |
| C3 Reid-McCann | Northern Ireland Department for the Economy PhD support; UK | 1 for stated review funding / B | Review reports no conflicts; heterogeneous underlying trials are not an independent-only dataset, and their complete financial chains were not verified |
| C4 Briskey | Angel Yeast, China; study Australia | 4 / D | Trial-existence/dose audit only; commercial efficacy excluded |
| C5 Bai | Angel Nutritional Fund, China | 4 / D | Trial-existence/dose audit only; commercial efficacy excluded |
| C6 Barsky | Lesaffre funding, supplied ingredient and employee coauthor; France; study Canada | 4 / D | Preprint and acute metabolic context only. Noninferiority depends on excluding one participant; all-13 analysis is inconclusive |
| C7–C8 Arla ingredient pages | Company sales; Denmark | 4 / D | Product identity and processing only; no independent benefit inference |
| C9 Health Canada assessment | Government, Canada; applicant-provided dossier | 1 / A for regulatory identity; dossier interested | Identifies milk-protein allergen issue; does not endorse efficacy |
| C10 FAO | UN agency; member-state and voluntary funding; HQ Rome, Italy; consultation funding not fully traced | Unknown consultation-level independence / B for methods | Scoring method only; expert ties and underlying data not fully re-audited |
| C11 EU regulation | Public legal institution, European Union | 1 / A for legal text | General protein claim, not source superiority |
| C12 FDA | US appropriations plus restricted industry user fees C24 | 2 / A for allergen facts | Legal accountability; no claim of protein-company sponsorship, no batch certification |
| C13 Health Canada allergy advice | Federal public body, Canada | 1 / A | Public-health mandate; not a precise individual probability |
| C14 NIDDK | Federal public health research body, US | 1 / A | Lactose explanation; no product testing |
| C15 eCFR | Federal legal record, US | 1 / A for regulation | Specified ingredient only; not generic retail approval |
| C16 levothyroxine label | Commercial manufacturer/repackager, US; DailyMed archive | 4 issuer / A for regulated warnings | Product-label food interaction; not a protein-supplement trial |
| C17 tranylcypromine label | Commercial drug label, US; DailyMed archive | 4 issuer / A for regulated warnings | Specific tyramine warning; not every yeast ingredient |
| C18 Pinckaers | TiFN public/private sponsors; Netherlands/France/US | 4 / D | Pea–milk comparator and funding trace; sponsors helped choose products/design. Additional author company ties; commercial efficacy excluded |
| C19 Angel fund page | Angel Nutritech commercial nutrition business; China | 4 / D | Own 2026 fund disclosure and sample support; historical grant contracts and supplier-payment terms remain unknown |
| C20 Arla corporate page | Company-owned, Denmark | 4 / D | Ownership/location self-disclosure; not clinical evidence |
| C21 Lesaffre ownership disclosures | Company and subsidiary; France | 4 / D | Family-ownership self-disclosure; individual share percentages not reconstructed |
| C22 FDA supplements page | US appropriations plus restricted industry user fees C24 | 2 / A for rules | Legal accountability; does not pre-test every product |
| C24 FDA funding explanation | US government plus restricted industry user fees | 2 / A for funding rules | Institutional self-disclosure; not efficacy evidence |
| C23 FSSAI portal | Public statutory authority, India | 1 / A for regulatory route | Exact ingredient/formulation eligibility requires checking |
FDA receives appropriations and legally restricted industry user fees; no protein-company sponsorship of these guidance pages is alleged. C24 Public agencies have accountability incentives but can face policy and institutional pressures. Researchers face novelty, publication and grant incentives. Industry disclosure is not inherently dishonest; the strict exclusion makes the verdict's source dependence visible. Relevant trials remain concentrated in a few countries and do not represent every population or formulation.
Regulatory context
FDA does not pre-approve US dietary supplements for safety or effectiveness. Ingredient specifications, facility registration and an agency's response to a particular food notification are not clinical endorsements. C15, C22
In India, the FSSAI regulatory route depends on the actual product category and ingredients. Overseas authorization cannot simply be treated as permission for the same formulation in India. The official portal is the starting point for verification; this comparison does not certify a retail product's compliance. C23
FAQ
Which one should I choose?
Start with whether extra protein is needed, then exclude incompatible allergens and assess the full product. Dietary preference, tolerability, cost per actual protein amount and test documentation can make one option more practical without making it clinically superior for everyone.
Is yeast protein just another plant protein?
It is fungal, not plant-derived. It may be a non-animal option, but keeping it separate prevents evidence from soy or pea being incorrectly attributed to yeast.
Is clear whey a fourth protein category?
No. It is a formulation within whey. Compare its actual ingredient and label rather than assigning an extra physiological benefit to a clear appearance. C7, C8
Are all three “complete”?
That word is too imprecise for a clinical ranking. Check amino-acid amounts, digestibility and actual protein content, and distinguish ingredient composition from outcomes in people. C10
Does the thinner independent yeast evidence mean it cannot work?
No. It means independent confirmation of particular benefits, doses and comparisons is missing from this audit. The honest conclusion is a research gap, not a verdict of zero nutritional value.
Can I mix them?
A mixed product is a new formulation with its own composition and allergen profile. Evidence for one ingredient does not automatically establish the mixture's outcome or its optimal ratio.
Sources and limitations
This is a targeted human-evidence and funding review, not a registered systematic review or an exhaustive trial census. It does not claim a completed external clinical review, independent batch certification or a current price comparison. Sources are used for their specific clinical, regulatory, product-identity or disclosure roles; unreported funding and procurement terms remain unknown.
Companion ingredient articles: Whey protein, Plant protein, Yeast protein. These published ingredient guides provide further context.
Source index
- C1 — Banaszek 2019
- C2 — Lynch 2020
- C3 — Reid-McCann 2025
- C4 — Briskey 2024
- C5 — Bai 2026
- C6 — Barsky 2026 preprint v1
- C7 — Arla whey isolate applications
- C8 — Arla hydrolysate for clear drinks
- C9 — Health Canada beta-lactoglobulin assessment
- C10 — FAO 2013 protein quality
- C11 — EU authorized protein claims
- C12 — FDA allergy guidance
- C13 — Health Canada pea allergy
- C14 — NIDDK lactose intolerance
- C15 — Specified baker's yeast protein rule
- C16 — Levothyroxine label May 2026
- C17 — Tranylcypromine label
- C18 — Pinckaers 2024 disclosures
- C19 — Angel nutrition fund
- C20 — Arla ownership and country
- C21 — Lesaffre family-ownership disclosure
- C22 — FDA supplement rules
- C23 — FSSAI official portal
- C24 — FDA funding and restricted user fees
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
